Granules at a Glance
Three characteristics define our brand’s promise: operational efficiencies driven; R&D focused; and multi-product delivery capability.
Granules India Ltd. is a vertically integrated pharmaceutical company, headquartered in Hyderabad, India. We manufacture Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs), distributed to quality conscious customers in both regulated and semi-regulated markets. We are dedicated to excellence in manufacturing, quality and customer service.
As Granules stands today, our business is bucketed into three areas; the Core business which comprises our ‘core molecules- Paracetamol, Ibuprofen, Metformin, Guaifenesin and Methocarbamol; the Emerging business that focuses on manufacturing APIs with a focus on vertical integration and the CRAMS segment, which focuses on contract research and manufacturing.
Our differentiating edge
We strive to provide access to safe, effective and affordable medicines to the people who need them.
Here is how our key strengths help us achieve our objective.
Vertically Integrated Model
An integrated value chain that has promoted us from an API manufacturer to a global pharmaceutical player.
Economies of Scale
Our facilities can accommodate large-scale customers with our industry-leading batch size of 6mt in PFIs.
Strong R&D Capabilities
Our dedicated research & development team is committed to developing products and process efficiencies to create a diverse range of cost-effective offerings. Our research effort drives our vision of becoming a cost effective, vertically integrated company.
Our current product basket, comprising of growth oriented stable APIs, PFIs and FDs cater to the needs of global giants. We are also working towards enhancing our offerings with more products that require strong technical backing.
As an initiative to take our focus on integration forward, we have also set up:-
Granules Consumer Healthcare (GCH)
GCH, our consumer health division, was established to leverage our efficiencies, scale, integration and relationship management.
Granules Pharmaceutical Inc (GPI)
We recently bought a facility in Chantilly, Virginia. Our objective is to focus on formulation R&D by leveraging a niche technology
Team strength of2,165+
World’s largestPFI Facility
Learn more about us
Our product-focused, vertically integrated business model has created a leadership position in several generic drugs. We have a strong presence in ‘first line of defence’ products,including Paracetamol, Ibuprofen, Guaifenesin and Metformin. We export nearly 60% of our revenue to the US and Europe. Our key customers include some of the leading generic, as well as, branded pharmaceutical companies. Our integrated model for manufacturing APIs, PFIs and Finished Dosages enables us to provide products across the value chain and enhances our competitiveness. We have emerged into a knowledge driven, R&D focused, multi-product organization, with inherent strength in efficient manufacturing of high-volume pharmaceutical products.
GCH, our consumer health division, was established to leverage our efficiencies, scale, integration and relationship management for our core products as well as other large-volume pharmaceutical products.While providing high-quality, cost-effective products has been the key goal at Granules for the past three decades, carrying forward to the retail front will let us work directly with the end customer and provide more innovative solutions. In addition to getting their private label supplies directly from us, retailers will have access to a responsive team that is adamant about making their business easier and more productive.
Granules has initiated two strategic moves by acquiring Auctus Pharma (now, officially amalgamated into Granules and referred to as ‘New API Business’) in February 2014 and by setting up a dedicated R&D center to focus on the development of this vertical. These moves are a part of our diversification strategy to strengthen our focus on vertical integration. The acquisition of Auctus Pharma gave us access to 12 APIs, as well as key intermediates in therapeutic categories, such as anti-histaminic, antihypertensive, anti-thrombotic, proton pump inhibitors, and anti-convulsants, among others. Our R&D centre, while working on making the current processes for existing products within the New API business more efficient has also been adding new APIs to the portfolio. A strong strategic intent of forward integration has been and will be the backbone of this segment.
We recently bought a facility in Chantilly, Virginia. Our objective is to focus on formulation R&D by leveraging a niche technologythat enables us to make dosage forms with specific release capabilities like pulsatile drug release in tablet and capsule dosage form, orally disintegrating modified release tablets (XR, MR, ER), modified release suspension and controlled substances capabilities in an abuse deterrent technology platform,all supported by “New API business,” to stay in line with our focus on integration.
We also have ventured into the CRAMS business through Granules-OmniChem, a 50-50 joint venture with Ajinomoto OmniChem - our partner, which is nearly 40 years of experience in CRAMS. Ajinomoto OmniChem works with branded pharmaceutical companies, and makes patent protected products for regulated markets. Going forward, when these products go off-patent, customers will be able to retain market share by shifting to the products made at Granules- OmniChem, by leveraging our expertise in efficient manufacturing.
Over the past 34 years, Granules has worked towards strengthening its core through its five products, and is, today, an integrated player with a strong market presence. With our focus on forward and backward integration, we are sowing seeds in new areas, segments and divisions to reach our targets.